INSP Stock Forecast & Price Target

Inspire Medical Systems, Inc. has demonstrated significant growth in its workforce, increasing employee count to 1,333 by the end of 2025, reflecting ongoing operational expansion. The company's advertising expenses rose by 21% year-over-year to $114.9 million in 2025, indicating a robust investment in marketing to drive sales in the growing global hypoglossal nerve stimulation (HGNS) market, expected to achieve a compound growth rate of 11% to 16% in the coming years. Furthermore, Inspire's focus on maintaining strong gross margins above 80% while ramping profitability positions the company favorably for sustainable double-digit revenue growth, supported by a strategically growing sales and marketing organization.

Inspire Medical Systems has revised its FY2026 revenue guidance downward from $1,003-1,013 million (+10-11% year-over-year) to a new range of $950-1,000 million (+4-10% year-over-year), primarily due to reimbursement uncertainties surrounding its new Gen 5 coding. The company faces significant headwinds as the potential adverse impact of coding changes may discourage ear, nose, and throat (ENT) specialists from performing its procedures, contributing to a decelerating domestic growth trajectory. Additionally, the lack of a fallback for the recently approved Nyxoah Genio implant and ongoing confusion with reimbursement processes further exacerbate the challenges faced by Inspire, justifying a more cautious outlook on its stock performance.